FDA Approves Freenome's Blood Test for Colorectal Cancer Screening
The U.S. FDA approved Freenome’s blood test for colorectal cancer screening in average-risk adults aged 45 and older, giving the company its first commercial product. Abbott will exclusively commercialize it in the U.S. this fall. Freenome said the test showed 81.1% sensitivity for colorectal cancer in a 48,000+ adult study. Abbott will pay Freenome a $100 million milestone tied to approval.
How this was made
The 30-second read
Why it matters
The approval is a de-risking regulatory milestone and sets a concrete commercialization timeline for Abbott, with a stated $100M milestone payment to Freenome tied to the approval.
Market read
Traders can reassess near-term commercialization expectations and competitive positioning in blood-based colorectal screening following the FDA approval and partner launch plan.
What to watch
Adoption will depend on clinician/payer uptake, patient compliance versus stool tests, and Abbott’s execution; the article does not provide pricing or reimbursement details beyond Medicare eligibility.
Background
FDA approval for average-risk adults aged 45+ gives Freenome its first commercial product, under a 2025 commercialization deal with Abbott.
Ticker impact
Abbott will exclusively commercialize Freenome’s SimpleScreen CRC in the U.S. this fall, expanding Abbott’s colorectal screening offering.
Moderately positive, with impact likely more gradual unless investors view it as a meaningful near-term revenue driver.
The article provides approval timing and exclusivity but no revenue/market-size figures; it does not quantify expected sales.
Market effects
Reinforces momentum for blood-based colorectal cancer screening and competitive pressure on existing liquid biopsy screening providers.
U.S.-focused commercialization and Medicare coverage criteria can accelerate adoption in the U.S. market.
Primarily U.S. regulatory and payer dynamics, but could influence global interest in similar screening platforms.
Counterpoint
Sensitivity for advanced precancerous growths is relatively low, which could limit adoption versus stool-based screening depending on real-world performance.
Key entities
- companyFreenome
FDA-approved blood-based colorectal cancer screening test provider; first commercial product and $100M milestone from Abbott.
- companyAbbott
Exclusive U.S. commercialization partner for SimpleScreen CRC launching this fall.
- companyGuardant Health
Competing provider referenced via its FDA-approved Shield blood test.
- regulatorFDA
Approved SimpleScreen CRC for average-risk adults aged 45 and older.
